| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(1 year, 7 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5874447 | SEBELA IRELAND LTD | 4-Phenylpiperidine compounds for treating depression |
Jun, 2017
(6 years ago) | |
Pexeva is owned by Sebela Ireland Ltd.
Pexeva contains Paroxetine Mesylate.
Pexeva has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Pexeva are:
- US5874447
Pexeva was authorised for market use on 03 July, 2003.
Pexeva is available in tablet;oral dosage forms.
Pexeva can be used as depression.
The generics of Pexeva are possible to be released after 04 May, 2025.
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 03 July, 2003
Treatment: Depression
Dosage: TABLET;ORAL
More Information on Dosage
PEXEVA family patents
